Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.8552W HIGH $208.63
Volume
36.69 K
Value Traded
25.07 K
Short % Float
2.66%
-6.63%Week
-28.38%1 Month
-24.7%3 Month
-22.6%6 Month
-99.95%5 Year
-99.95%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
22.53 M
EPS (TTM)
45.24
P/E Ratio
0.12
Ent. Value
-68.78 M
Total Shares
4.05 M
Float Shares
3.76 M
Insiders
7.21%
Institutions
24.67%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
KYNB Catalyst Timeline
Dated clinical, regulatory and corporate events for Kyntra Bio, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kyntra Bio, Inc.
384Total events
6Upcoming
136Tier-1 (high impact)
2015 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Management ChangeCorporate
Andrew E. Singer appointed to Board of Directors as independent director and Audit Committee member
▲Debt Royalty FinancingCorporate
Amendment and restatement of royalty financing agreement with NQ Project Phoebus, L.P.
●Quarterly UpdateCorporate
Conference call and webcast presentation to discuss Q2 2026 financial results
◆Trial InitiationRoxadustatApprovedTrial
Initiation of pivotal Phase 3 trial of roxadustat in LR-MDS with high transfusion burden
anemia due to lower-risk myelodysplastic syndromes (LR-MDS) with high transfusion burdensource ↗
●Quarterly UpdateCorporate
Cash, cash equivalents, investments, and accounts receivable of $95.7 million as of June 30, 2026
◆Poster PresentationRoxadustatApprovedPresentation
Poster presentation of post-hoc analysis of MATTERHORN trial at EHA 2026
anemia due to lower-risk myelodysplastic syndromes (LR-MDS)source ↗
▲Debt Royalty FinancingCorporate
Settlement of all obligations related to FibroGen Europe bankruptcy for approximately $0.1 million
◆FDA Feedback ReceivedRoxadustatApprovedFDA Meeting
FDA feedback received on pivotal Phase 3 trial protocol for roxadustat in LR-MDS
anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burdensource ↗
◆Oral PresentationPresentation
Kyntra Bio to present at 25th Annual Needham Virtual Healthcare Conference
▼BankruptcyCorporate
FibroGen Europe voluntarily submitted for bankruptcy to Finnish bankruptcy court
●Quarterly UpdateCorporate
Conference call and webcast presentation to discuss financial results and business update
◆Enrollment UpdateFG-3246Trial
Phase 2 monotherapy trial actively enrolling
metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲Orphan Drug DesignationRoxadustatApprovedDesignation
Orphan Drug Designation granted by FDA for MDS
myelodysplastic syndromes (MDS)source ↗
●NDA SubmissionRoxadustatApprovedRegulatory Filing
Pivotal Phase 3 clinical trial protocol submitted to FDA
anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burdensource ↗
▲Poster PresentationFG-3246Presentation
Poster presentation of Phase 1b/2 data of FG-3246 + enzalutamide at ASCO GU 2026
metastatic castration-resistant prostate cancersource ↗
▲Oral PresentationFG-3246Presentation
Positive results from investigator-sponsored study of FG-3246 in combination with enzalutamide presented at ASCO GU in February 2026
metastatic castration-resistant prostate cancer (mCRPC)source ↗
◆Oral PresentationFG-3246Presentation
Topline results from FG-3246 + enzalutamide Phase 1b/2 study to be presented at ASCO GU
metastatic castration-resistant prostate cancer (mCRPC)source ↗
◆Topline ReadoutFG-3246Clinical Data
Topline results from investigator-sponsored study of FG-3246 + enzalutamide expected at medical conference in 1Q 2026
mCRPCsource ↗
▲Oral PresentationRoxadustatApprovedPresentation
Additional data from Phase 3 MATTERHORN study presented at EHA Congress 2026
lower-risk myelodysplastic syndromes (LR-MDS) with high transfusion burden (HTB)source ↗
◆Topline ReadoutFG-3246Clinical Data
Topline results from Phase 2 portion of investigator-sponsored study of FG-3246 in combination with enzalutamide expected in 2H 2025
metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲Trial InitiationFG-3246Trial
Initiated Phase 2 monotherapy trial of FG-3246 in mCRPC
metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲FDA Feedback ReceivedRoxadustatApprovedFDA Meeting
Reached agreement with FDA on design elements for pivotal Phase 3 trial of roxadustat in LR-MDS
anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high RBC transfusion burdensource ↗
●Timing GuidanceRoxadustatApprovedPresentation
Final protocol submission for pivotal Phase 3 trial of roxadustat anticipated in 4Q 2025
anemia in patients with LR-MDS and high transfusion burdensource ↗
◆Topline ReadoutFG-3246Clinical Data
Topline results from Phase 2 portion of investigator-sponsored study of FG-3246 + enzalutamide in mCRPC expected in 4Q 2025
metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲Other Regulator MilestoneEx-US Regulatory
China SAMR approval of sale of FibroGen China to AstraZeneca
●Quarterly UpdateCorporate
Q2 2025 financial results and business update conference call on August 11, 2025
◆Trial InitiationFG-3246Trial
Initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC expected in 3Q 2025
metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲Type C MeetingRoxadustatApprovedFDA Meeting
Positive Type-C meeting with FDA in July 2025; agreement on pivotal Phase 3 trial design
anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high RBC transfusion burdensource ↗
◆Trial InitiationFG-3246Trial
Initiation of Phase 2 monotherapy trial of FG-3246 expected by mid-2025
metastatic castration-resistant prostate cancer (mCRPC)source ↗
◆FDA Feedback ReceivedRoxadustatApprovedFDA Meeting
Plan to meet with FDA in 2Q 2025 to determine next steps for roxadustat in LR-MDS
anemia associated with lower-risk myelodysplastic syndrome (LR-MDS)source ↗
▲PublicationFG-3246Presentation
Publication of Phase 1 monotherapy study results of FG-3246 in JCO
metastatic castration-resistant prostate cancer (mCRPC)source ↗
◆Trial InitiationFG-3246Trial
Initiation of Phase 2 monotherapy dose optimization study expected by mid-2025
metastatic castration-resistant prostate cancersource ↗
▲PublicationFG-3246Presentation
Publication of Phase 1 monotherapy study results in Journal of Clinical Oncology
metastatic castration-resistant prostate cancersource ↗
▲Orphan Drug DesignationRoxadustatApprovedDesignation
FDA grants Orphan Drug Designation for roxadustat in MDS
myelodysplastic syndromes (MDS)source ↗
●NDA SubmissionRoxadustatApprovedRegulatory Filing
Pivotal Phase 3 trial protocol for roxadustat submitted to FDA
anemia in lower-risk MDS with high transfusion burdensource ↗
◆Trial InitiationFG-3246Trial
Initiation of Phase 2 monotherapy dose optimization study of FG-3246 anticipated in 1Q 2025
metastatic castration-resistant prostate cancer (mCRPC)source ↗
◆FDA ApprovalRoxadustatApprovedFDA Decision
Approval decision for roxadustat in CIA in China expected in early 2025
chemotherapy-induced anemia (CIA)source ↗
Past FDA Catalysts and PDUFA Decisions
How KYNB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-12 | roxadustat | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
4
Drugs Scored
rNPV / MCap
Top Drug
Top 22%
Micro Cap(rank 145 of 656)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FG-3246 Small moleculeNCT06842498 | Metastatic Castration-Resistant Prostate Cancer | Phase 2 | RECRUITING | 75 | Mar 31, 2028 | ||||||
| Roxadustat Small moleculeNCT07722988 | Myelodysplastic Syndromes | Phase 3 | NOT YET_RECRUITING | 201 | Dec 1, 2032 | ||||||
| Pamrevlumab Monoclonal antibodyCompletedNCT03941093 | Pancreatic Cancer Non-resectable | Phase 3 | COMPLETED | 284 | Jun 11, 2024 | ||||||
| FG-3019 Monoclonal antibodyCompletedNCT00074698 | Idiopathic Pulmonary Fibrosis | Phase 2 | COMPLETED | 111 | May 1, 2004 | ||||||
| Pamrevlumab Monoclonal antibodyCompletedNCT01890265 | Idiopathic Pulmonary Fibrosis | Phase 2 | COMPLETED | 160 | Nov 16, 2017 | ||||||
| FG-3019 Monoclonal antibodyCompletedNCT00102297 | Diabetes Mellitus | Phase 1 | COMPLETED | 58 | Jun 1, 2007 | ||||||
| FG-3019 Monoclonal antibodyCompletedNCT01181245 | Locally Advanced or Metastatic Pancreatic Cancer | Phase 1 | COMPLETED | 50 | Jun 1, 2014 | ||||||
| FG-3019 Monoclonal antibodyCompletedNCT02210559 | Pancreatic Cancer (Unresectable) | Phase 1 | COMPLETED | 37 | Dec 15, 2021 | ||||||
| SEPO Small moleculeCompletedNCT05301517 | Chemotherapy Induced Anemia | Phase 3 | COMPLETED | 159 | Apr 21, 2023 | ||||||
| Roxadustat Small moleculeMarketedNCT02780726 | Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia | Phase 3 | COMPLETED | 56 | Aug 2, 2017 | ||||||
| Roxadustat Small moleculeMarketedNCT02278341 | Anemia | Phase 3 | COMPLETED | 838 | Jul 6, 2018 | ||||||
| Roxadustat Small moleculeMarketedNCT02780141 | ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia | Phase 3 | COMPLETED | 75 | Dec 12, 2017 | ||||||
| Roxadustat Small moleculeMarketedNCT02779764 | Hemodialysis Patients With Renal Anemia | Phase 3 | COMPLETED | 164 | Nov 28, 2017 | ||||||
| Roxadustat Small moleculeMarketedNCT02952092 | Hemodialysis Chronic Kidney Disease Patients With Anemia | Phase 3 | COMPLETED | 303 | Mar 15, 2018 | ||||||
| Roxadustat Small moleculeMarketedNCT01887600 | Anemia in Chronic Kidney Disease in Non-dialysis Patients | Phase 3 | COMPLETED | 1,210 | Nov 1, 2017 | ||||||
| Roxadustat Small moleculeMarketedNCT04410198 | Anemia Associated With End Stage Renal Disease | Phase 3 | COMPLETED | 486 | Oct 11, 2021 | ||||||
| Roxadustat Small moleculeMarketedNCT02052310 | Anemia in Incident Dialysis Patients | Phase 3 | COMPLETED | 1,043 | Sep 21, 2018 | ||||||
| Roxadustat Small moleculeMarketedNCT02273726 | CKD Anemia in Stable Dialysis Patients | Phase 3 | COMPLETED | 741 | Sep 19, 2018 | ||||||
| Roxadustat Small moleculeMarketedNCT01750190 | CKD Anemia | Phase 3 | COMPLETED | 922 | Sep 24, 2018 | ||||||
| FG-4592 Small moleculeMarketedNCT03303066 | Anemia | Phase 3 | COMPLETED | 502 | Feb 8, 2023 | ||||||
| Roxadustat Small moleculeMarketedNCT04076943 | Chemotherapy Induced Anemia | Phase 2 | COMPLETED | 92 | Apr 23, 2021 | ||||||
| FG-4592 Small moleculeMarketedNCT01596855 | Anemia in End Stage Renal Disease | Phase 2 | COMPLETED | 96 | Jan 1, 2013 | ||||||
| FG-4592 Small moleculeMarketedNCT01599507 | Anemia in Chronic Kidney Disease | Phase 2 | COMPLETED | 91 | Jan 1, 2013 | ||||||
| Roxadustat Small moleculeMarketedNCT01147666 | End Stage Renal Disease | Phase 2 | COMPLETED | 161 | Oct 15, 2012 | ||||||
| Roxadustat Small moleculeMarketedNCT01414075 | Dialysis | Phase 2 | COMPLETED | 60 | Jan 10, 2013 |
Clinical Trial Results
Readouts, endpoints and source filings for every KYNB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| roxadustat Orphan | anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden (HTB) | Phase 3 | 2026-08-13 | patients treated with roxadustat showed a clinically meaningful improvement in transfusion independence (TI) in patients with LR-MDS and HTB compared to placebo. Similar rates of TI for patients treated with roxadustat were observed in both ring sideroblast positive (RS+) and ring sideroblast negative (RS-) disease.Read More | Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business UpdateRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Wettig ThaneDirector, Officer (CEO) | Buy | -2,800 27,203 held | $7.09 | 05/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KYNB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in KYNB for Q2 2026. | ||||
KYNB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KYNB ranks across every disease it competes in
Competitive Position is a premium feature
See how KYNB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKYNB News
KYNBKyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors
Kyntra Bio has appointed Andrew E. Singer, MBA, to its Board of Directors, effective October 1, 2026. Singer, a seasoned executive with over 25 years in biotechnology finance, will contribute to the company's strategic priorities. Maykin Ho, Ph.D., has stepped down from the board after nearly eight years of service. Kyntra Bio continues to enhance its focus on its oncology and rare disease pipeline.
Read more →KYNB▲ +7.3%on this news
Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Kyntra Bio will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026, in New York. CEO Thane Wettig is scheduled to present on September 15 at 4:00 PM ET. The company will also hold one-on-one meetings with investors. Kyntra Bio focuses on novel therapies for oncology and rare diseases.
Read more →KYNBKyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation
Kyntra Bio has amended its royalty financing agreement, reducing maximum payments from $125 million to $65 million. An upfront payment of $42.6 million has been made, enhancing the company's cash position and extending its cash runway into the fourth quarter of 2027. The company continues to advance its clinical pipeline in oncology and rare diseases despite recent challenges, including the bankruptcy of its subsidiary, FibroGen Europe.
Read more →KYNBKyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Kyntra Bio reported its second quarter 2026 financial results, highlighting progress in its oncology pipeline, particularly with FG-3246 and roxadustat. The company is on track for pivotal trials in the fourth quarter of 2026 and presented positive data from the Phase 3 MATTERHORN study. Financially, Kyntra reported a net income of $12 million and sufficient cash reserves to support operations until 2028.
Read more →KYNBKyntra Bio to Report Second Quarter 2026 Financial Results
Kyntra Bio, Inc. will report its second quarter 2026 financial results on August 13, followed by a conference call to discuss the outcomes. The company is focused on developing therapies for oncology and rare diseases, with ongoing trials for roxadustat and FG-3246. A live Q&A session will be held after the presentation.
Read more →KYNB▲ +5.5%on this news
Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes
Kyntra Bio presented new data from the Phase 3 MATTERHORN trial, demonstrating that roxadustat significantly improves transfusion independence in patients with lower-risk myelodysplastic syndromes (LR-MDS), regardless of ring sideroblast status. The findings will be showcased at the upcoming European Hematology Association Congress. The pivotal Phase 3 trial protocol is being finalized based on FDA feedback.
Read more →KYNBKyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Kyntra Bio reported its first quarter 2026 financial results, highlighting progress in its clinical pipeline. The Phase 2 trial of FG-3246 for metastatic castration-resistant prostate cancer is advancing, with interim analysis expected in late 2026. Additionally, the company is finalizing the Phase 3 trial protocol for roxadustat based on FDA feedback. Financially, Kyntra has a robust cash position, ensuring operations through 2028.
Read more →KYNBKyntra Bio to Report First Quarter 2026 Financial Results
Kyntra Bio, Inc. will announce its first quarter 2026 financial results on May 11, 2026, after market close. Following the announcement, the management team will host a conference call and webcast to discuss the results and provide a business update. The company is focused on developing therapies for oncology and rare diseases, with ongoing trials for its drugs.
Read more →KYNB▲ +5.5%on this news
Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference
Kyntra Bio will present at the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026. CEO Thane Wettig is scheduled to deliver a presentation on April 13 at 1:30 PM EDT. The management team will also be available for one-on-one meetings with investors. A replay of the presentation will be accessible on the company's website for 90 days.
Read more →KYNBKyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Kyntra Bio reported its fourth quarter and full year 2025 financial results, highlighting the ongoing Phase 2 trial of FG-3246 for metastatic castration-resistant prostate cancer, which is on schedule for interim analysis in late 2026. The company also submitted a Phase 3 trial protocol for roxadustat for anemia in lower-risk myelodysplastic syndromes. Financially, Kyntra Bio reported a net loss of $14.6 million for Q4 2025, with total revenue declining compared to the previous year. The company maintains a robust cash position, expected to sustain operations until 2028.
Read more →KYNB▲ +7.3%on this news
Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results
Kyntra Bio will report its fourth quarter and full year 2025 financial results on March 16, 2026. The company will host a conference call at 5:00 PM ET to discuss these results and provide updates on its corporate performance. Kyntra Bio is known for its development of therapies for oncology and rare diseases, including roxadustat and FG-3246.
Read more →KYNB▼ -9.6%on this news
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
Kyntra Bio announced positive preliminary data from a Phase 1b/2 study of FG-3246 combined with enzalutamide for metastatic castration-resistant prostate cancer. The study showed a median radiographic progression-free survival of 10.1 months in patients with one prior ARPI. The results will be presented at the ASCO GU 2026 symposium, highlighting the potential of FG-3180 as a biomarker.
Read more →KYNB▲ +6.3%on this news
Kyntra Bio to Participate in Upcoming Investor Conferences - February 17, 2026
Kyntra Bio (KYNB) has announced its participation in two upcoming investor conferences, including the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Global Healthcare Conference. The management team will also be available for one-on-one meetings during these events. Kyntra Bio is focused on developing novel therapies, including ongoing trials for roxadustat and FG-3246.
Read more →KYNBFibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum -Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare disease
FibroGen has officially rebranded as Kyntra Bio, effective January 8, 2026, emphasizing its focus on oncology and rare disease therapies. Key highlights include extending its cash runway into 2028, receiving Orphan Drug Designation for its treatment of myelodysplastic syndromes, and ongoing clinical trials for its CD46 targeting ADC and PET imaging agent. The company is also refreshing its corporate branding to align with its strategic direction moving forward. This transformation represents the culmination of significant changes within the company during the past year.
Read more →KYNBFibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update
FibroGen reported its financial results for Q3 2025, highlighting a successful sale of its Chinese operations to AstraZeneca for $220 million. The company has initiated a Phase 2 trial for FG-3246, targeting metastatic castration-resistant prostate cancer, and reached an agreement with the FDA on key elements for a Phase 3 trial of roxadustat. Financially, FibroGen maintained a cash runway into 2028, although it recorded a net loss of $13.1 million for the quarter and relatively low revenue from continuing operations.
Read more →KYNBFibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million
FibroGen has successfully completed the sale of its subsidiary in China to AstraZeneca for approximately $220 million, marking a significant boost to its financial position. The transaction involved $85 million in enterprise value and $135 million in net cash. The company plans to use the proceeds to extend its cash runway into 2028 and is on track to initiate a Phase 2 trial for FG-3246 in metastatic castration-resistant prostate cancer. Additionally, FibroGen is preparing to file a Phase 3 protocol for roxadustat in treating anemia in patients with lower-risk myelodysplastic syndromes in late 2025.
Read more →KYNBFibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation
FibroGen, Inc. announced that the China State Administration for Market Regulation has approved the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited. The transaction is part of a prior agreement signed on February 20, 2025, and is expected to close in the third quarter of 2025, pending final conditions. FibroGen remains focused on advancing its therapies for cancer and anemia, including ongoing evaluations for its drugs in various indications.
Read more →KYNBFibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update
FibroGen, Inc. has announced its financial results for the second quarter of 2025, reporting a total revenue of $1.3 million and a net loss of $13.7 million. The company expects to complete the sale of its subsidiary in China to AstraZeneca for approximately $210 million, which would extend its cash runway into 2028. Additionally, FibroGen is set to commence a Phase 2 trial for FG-3246, a promising treatment for metastatic castration-resistant prostate cancer, and has made significant progress with roxadustat towards a Phase 3 trial for anemia in patients with lower-risk myelodysplastic syndromes. The developments position FibroGen for potential value creation for patients and shareholders.
Read more →KYNBFibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors
FibroGen has appointed Dr. Michael Kauffman, an experienced biotech leader, to its Board of Directors as of June 4, 2025. His extensive background in drug development, particularly in oncology, is expected to contribute positively to FibroGen's efforts towards clinical milestones and enhance its pipeline. The company sees this appointment as a strategic move to drive its turnaround strategy. Kauffman's previous leadership roles in notable biotech companies underline his suitable expertise for this position.
Read more →KYNBFibroGen Reports First Quarter 2025 Financial Results and Provides Business Update
FibroGen, Inc. has reported its financial results for Q1 2025 and a strategic update. The company has seen a $25 million increase in the anticipated sale value of its subsidiary in China to AstraZeneca, bringing the total to approximately $185 million. Additionally, FibroGen plans to initiate a Phase 2 study for FG-3246, a promising ADC targeting metastatic castration-resistant prostate cancer, expected to start in Q3 2025. The company also filed a Type-C meeting request with the FDA regarding roxadustat for treating anemia associated with lower-risk myelodysplastic syndromes, aiming for feedback in the same quarter.
Read more →About Kyntra Bio, Inc.
Headquarters350 BAY STREET, SAN FRANCISCO, CA, 94133
BIOPHARMAWATCH ELITE PLUS
Trade the next KYNB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime